Prevention of contrast media nephrotoxicity - The story so far

Clinical Radiology

Volumn 59, Issue 5, 2004, Pages 381-389

  Morcos, Sameh K ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Acetylcysteine; Adenosine; Contrast media; Endothelins; Haemofiltration; Nephrotoxicity

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ACETYLCYSTEINE; ADENOSINE RECEPTOR BLOCKING AGENT; ANTIOXIDANT; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIATRIZOATE; DILTIAZEM; DIMERIC NONIONIC CONTRAST MEDIUM; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; FUROSEMIDE; IOPROMIDE; IOXAGLIC ACID; MANNITOL; MONOMERIC NONIONIC CONTRAST MEDIUM; NITRENDIPINE; PROSTAGLANDIN E1; SB 209679; SODIUM CHLORIDE; THEOPHYLLINE; UNCLASSIFIED DRUG;

BODY WEIGHT; CLINICAL TRIAL; DOSE RESPONSE; HEART ARRHYTHMIA; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYDRATION; HYPOTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FUNCTION TEST; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SCREENING TEST; TACHYCARDIA;

EID: 2342438784     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2003.11.005     Document Type: Review

References (46)

1. Morcos SK. Contrast media-induced nephrotoxicity-questions and answers. Br J Radiol 1998;71:357-65.
2. Morcos SK, Thomsen HS, Webb JA, et al. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 1999; 9:1602-13.
3. Aspelin P, Aubry P, Fransson SG, Strasser R, Wellinbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-9.
4. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701-3.
5. Oldroyd S, Haylor J, Morcos SK, El Nahas AM. Reduced depression of renal function by iotrolan in the isolated rat kidney. Eur J Radiol 1994;18:64-9.
6. Morcos SK, Dawson P, Pearson JD, et al. The hemodynamic effects of iodinated water soluble radiographic contrast media: a review. Eur J Radiol 1998;29:31-46.
7. Cigarroa RG, Lange RA, Williama RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86:649-52.
8. Katholi RE, Taylor GJ, Thomas Woods W, et al. Nephrotoxicity of non-ionic low-osmolality versus ionic high-osmolality contrast media: a prospective double blind randomized comparison in human beings. Radiology 1993;186:183-7.
9. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxic and atheroembolism - a critical review. Am J Kidney Dis 1994;24:713-27.
10. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997; 103:368-75.
11. Wang Y-X, Jia Y-F, Chen K-M, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001;74:1103-8.
12. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality, a cohort analysis. J Am Med Assoc 1996; 257:1489-94.
13. Lee JK, Warshauer DM, Bush Jr WH, McClennan BL, Choyke PL. Determination of serum creatinine level before intravenous administration of iodinated contrast medium. A survey. Invest Radiol 1995;30:700-5.
14. Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Tech Urol 1998;4:65-9.
15. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol and furosemide on acute decrease in renal function induced by radiocontrast agents. N Eng J Med 1994; 331:1416-20.
16. Erley CM. Does hydration prevent radiocontrast-induced acute renal failure? Nephrol Dial Transplant 1999;14:1064-6.
17. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36.
18. Morcos SK, Thomsen HS, Webb JAW, Members of Contrast Media Safety Committee of the European Society of Urogenital Radiology (ESUR). Dialysis and contrast media. Eur Radiol 2002;12:3026-30.
19. Dehnarts T, Keller E, Gondolf K, Schiffner T, Pavenstadt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 1998;13:358-62.
20. Vogt B, Ferrari P, Schonholzer C, et al. Pre-emptive haemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 2001; 111:692-8.
21. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Eng J Med 2003;349:1333-40.
22. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989;4:1030-6.
23. Carraro M, Mancini W, Aretro M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant 1996;11:444-8.
24. Weisberg L, Kurnik PB, Kurnik RC. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259-65.
25. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002;55:169-73.
26. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
27. 1: a randomized, double-blind, placebo-controlled study. Am J Therap 2001;8:155-62.
28. Oldroyd SD, Fang L, Haylor JL, Yates MS, El Nahas AM, Morcos SK. Effects of adenosine receptor antagonists on the responses to contrast media in the isolated rat kidney. Clin Sci 2000;98:303-11.
29. Arakawa K, Suzuki H, Naitoh M, et al. Role of adenosine in the renal responses to contrast medium. Kidney Int 1996;49:1199-206.
30. Kathloli RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995;195:17-22.
31. Huber W, Ilgmann K, Page M, et al. Effect of theophylline on contrast material-induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blind study. Radiology 2002;223:772-9.
32. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant 1999;14:1146-9.
33. Oldroyd SD, Morcos SK. Endothelin: what does the radiologist need to know? Br J Radiol 2000;73:1246-51.
34. Oldroyd S, Slee SJ, Haylor J, Morcos SK, Wilson C. Role for endothelin in the renal responses to radiocontrast media in the rat. Clin Sci 1994;87:427-34.
35. Oldroyd SD, Haylor JL, Morcos SK. The acute effect of ioversol on kidney function: role of endothelin. Eur J Radiol 1995;19:91-5.
36. Oldroyd SD, Haylor JL, Morcos SK. Bosentan, an orally active endothelin antagonist: effect on renal response to contrast media. Radiology 1995;196:661-5.
37. Wang A, Holcslaw T, Bashore TM, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000;57:1675-80.
38. Haylor JL, Morcos SK. Endothelin antagonism and contrast nephropathy. Kidney Int 2000;58:2239.
39. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and nephrotoxic effects of radiographic contrast agents-a new use for an old drug. N Engl J Med 2000;343:210-1.
40. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Lierbermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
41. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART Trial). Am J Cardiol 2002;89:356-8.
42. Kay J, Chow WH, Lo SK, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. A randomized controlled trial. J Am Med Assoc 2003;289:553-8.
43. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
44. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
45. Birck R, Krzossok S, Markowetz F, Schnulle P, Woude FJVD, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;303:598-603.
46. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.